Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines

Anti-Cancer Drugs

Volumn 9, Issue 5, 1998, Pages 457-463

  Viale, Maurizio ^a   Pastrone, Ilaria ^a   Pellecchia, Caterina ^a   Vannozzi, Maria O ^a   Cafaggi, Sergio ^b   Esposito, Mauro ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Anticancer drugs; DPR; In vitro assay; Synergism

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PLATINUM DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0031846776     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199806000-00013     Document Type: Article

References (12)

1. Cafaggi S, Esposito M, Parodi B, et al. Synthesis and antitumor activity of a new cis-diammineplatinum(II) complex containing procaine hydrochloride. Anticancer Res 1992; 12: 2285-92.
2. Viale M, Vannozzi MO, Merlo F, Cafaggi S, Parodi B, Esposito M. Cisplatin combined with the new cisplatin-procaine complex DPR: in vitro and in vivo studies. Eur J Cancer 1996; 13: 2327-33.
3. Viale M, Cafaggi S, Parodi B, Esposito M. Cytotoxicity and cellular accumulation of a new cis-diammineplatinum(II) complex containing procaine in murine LI210 cells sensitive and resistant to cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 1995; 35: 371-6.
4. Zhang JG, Esposito M, Cafaggi S, Lindup WE. Comparison of the toxicities of cisplatin and a new cisplatin-procaine complex to rat renal cortical slices. Hum Exp Toxicol 1996; 15: 59-63.
5. Viale M, Melioli G, Pasquetti W, Meta M, Cafaggi S, Esposito M. Modifications of cell cycle induced by DPR, a new platinum-triamine complex containing procaine. Int J Oncol 1994; 4: 1047-51.
6. Hussain RF, Nouri AME, Oliver RTD. A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 1993; 160: 89-96.
7. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41: 93-141.
8. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981; 35: 269-335.
9. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-5.
10. Perez RP, Perez KM, Handel LM, Hamilton TC. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol 1992; 29: 430-4.
11. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994; 69: 299-306.
12. Lidor YJ, Shpall EJ, Peters WP, Bast Jr RC. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 1991; 49: 704-10.